Lyell Immunopharma, Inc. (LYEL)

11.04 0.01 (0.05%)

As of 2026-11-02 11:42:52 EST

Lyell Immunopharma, Inc. is an American clinical-stage biopharmaceutical company headquartered in South San Francisco, California. Founded in 2018, the company develops next-generation cell therapies, including CAR T cell (chimeric antigen receptor therapies), using technologies intended to improve T cell persistence, function, and resistance to exhaustion. Its pipeline includes therapies being developed for hematologic malignancies and solid tumors.

Traded asNasdaq: LYEL
ISINUS55083R2031
CIK0001806952
LEI—
EIN833006753
SectorBiotechnology
IndustryPharmaceutical Preparations
CEOLynn Seely
Employees—
Fiscal Year End1231
Address201 HASKINS WAY, SOUTH SAN FRANCISCO, CA, 94080
Phone650 695-0677
Websitehttps://lyell.com/
Stock Quotes
trading_symbolregistrant_nametimepricechangepercentage_change
LYELLyell Immunopharma, Inc.2026-11-02 11:42:5211.040.010.05
This is a preview of the latest data. Subscribe to access the full data.
Company Information
trading_symbolcentral_index_keyregistrant_nameisin_numberlei_numberein_numberexchangesic_codesic_descriptionfiscal_year_endstate_of_incorporationaddress_streetaddress_cityaddress_stateaddress_zip_codeaddress_countryaddress_country_codephone_numbermailing_addressbusiness_addressformer_nameindustryfounding_datechief_executive_officernumber_of_employeeswebsitemarket_capshares_issuedshares_outstandingdescriptionupdate_time
LYEL0001806952Lyell Immunopharma, Inc.US55083R2031—833006753Nasdaq2834Pharmaceutical Preparations1231DE201 HASKINS WAYSOUTH SAN FRANCISCOCA94080UNITED STATESUS650 695-0677201 HASKINS WAY, SOUTH SAN FRANCISCO, CA, 94080201 HASKINS WAY, SOUTH SAN FRANCISCO, CA, 94080—Biotechnology2018Lynn Seely—https://lyell.com/129,000,00023,397,00024,505,141Lyell Immunopharma, Inc. is an American clinical-stage biopharmaceutical company headquartered in South San Francisco, California. Founded in 2018, the company develops next-generation cell therapies, including CAR T cell (chimeric antigen receptor therapies), using technologies intended to improve T cell persistence, function, and resistance to exhaustion. Its pipeline includes therapies being developed for hematologic malignancies and solid tumors. 2026-10-30 04:59:02
This is a preview of the latest data. Subscribe to access the full data.
LYEL Stock Price (End-of-Day)
This is a preview of the latest data. Subscribe to access the full data.
LYEL Stock Price (1-Minute)
This is a preview of the latest data. Subscribe to access the full data.
Market Cap
Fiscal YearMarket CapChange In Market CapPercentage Change In Market CapShares OutstandingChange In Shares OutstandingPercentage Change In Shares Outstanding
2025129,000,000-177,000,000-57.843123,307,143-271,921,725-92.1054
2024306,000,000-348,000,000-53.211295,228,86841,132,55716.1878
2023654,000,000-446,000,000-40.5455254,096,3114,487,0641.7976
This is a preview of the latest data. Subscribe to access the full data.
Executive Compensation
Executive NameExecutive PositionFiscal YearSalaryBonusStock AwardsIncentive Plan CompensationOther CompensationTotal Compensation
Gary LeeChief Scientific Officer2025520,015062,269260,0006,7901,942,621
Lynn SeelyDirector, President, Chief Executive Officer2025690,1730186,806414,00023,7354,222,265
Stephen HillChief Operating Officer2025529,473062,269291,5009,5912,076,439
Stephen HillChief Operating Officer2024516,738094,800226,4007,3041,342,842
Lynn SeelyDirector, President, Chief Executive Officer2024675,9620474,000324,00021,4141,495,376
This is a preview of the latest data. Subscribe to access the full data.
Employee Count
Fiscal YearEmployee Count
2025161
2024300
2023224
This is a preview of the latest data. Subscribe to access the full data.
Income Statements
Fiscal Year202520242023
Revenue36,00061,000130,000
Cost Of Revenue———
Gross Profit36,00061,000130,000
Research And Development Expenses158,675,000171,603,000182,945,000
General And Administrative Expenses45,135,00052,041,00066,983,000
Operating Expenses269,440,000358,816,000247,138,000
Operating Income-269,404,000-358,755,000-247,008,000
Net Income-274,448,000-342,994,000-234,632,000
Earnings Per Share Basic-16.06-1.31-0.93
Earnings Per Share Diluted-16.06-1.31-0.93
Weighted Average Shares Outstanding Basic17,093,000261,480,000250,983,000
Weighted Average Shares Outstanding Diluted17,093,000261,480,000250,983,000
This is a preview of the latest data. Subscribe to access the full data.
Balance Sheet Statements
Fiscal Year202520242023
Cash And Cash Equivalents60,181,000105,597,000145,647,000
Marketable Securities Current187,039,000264,930,000400,576,000
Accounts Receivable———
Inventories———
Non Trade Receivables———
Other Assets Current13,719,0009,067,0008,463,000
Total Assets Current260,939,000379,594,000554,686,000
Marketable Securities Non Current013,014,00016,506,000
Property Plant And Equipment34,771,00048,200,000102,654,000
Other Assets Non Current4,886,0004,622,0004,235,000
Total Assets Non Current79,113,000111,265,000195,343,000
Total Assets340,052,000490,859,000750,029,000
Accounts Payable2,893,0005,366,0004,817,000
Deferred Revenue———
Short Term Debt———
Other Liabilities Current———
Total Liabilities Current49,412,00053,788,00034,519,000
Long Term Debt———
Other Liabilities Non Current517,0003,253,0003,664,000
Total Liabilities Non Current42,438,00054,247,00060,558,000
Total Liabilities91,850,000108,035,00095,077,000
Common Stock2,00029,00025,000
Retained Earnings-1,619,554,000-1,345,106,000-1,002,112,000
Accumulated Other Comprehensive Income242,000291,000-94,000
Total Shareholders Equity248,202,000382,824,000654,952,000
This is a preview of the latest data. Subscribe to access the full data.
Cash Flow Statements
Fiscal Year202520242023
Depreciation And Amortization11,539,00019,631,00020,250,000
Share Based Compensation Expense41,829,00033,144,00047,084,000
Other Non Cash Income Expense———
Change In Accounts Receivable———
Change In Inventories———
Change In Non Trade Receivables———
Change In Other Assets-2,823,000-1,775,000-3,125,000
Change In Accounts Payable-2,339,000-3,234,0001,464,000
Change In Other Liabilities-7,642,000-1,250,000-719,000
Cash From Operating Activities-150,024,000-162,394,000-163,694,000
Purchases Of Marketable Securities278,899,000394,707,000476,880,000
Sales Of Marketable Securities374,684,000548,941,000663,614,000
Acquisition Of Property Plant And Equipment780,000464,0002,686,000
Acquisition Of Business———
Other Investing Activities———
Cash From Investing Activities54,097,000122,424,000184,048,000
Tax Withholding For Share Based Compensation1,00076,000457,000
Payments Of Dividends———
Issuance Of Common Stock50,000,0001,248,0001,894,000
Repurchase Of Common Stock———
Issuance Of Long Term Debt———
Repayment Of Long Term Debt———
Other Financing Activities———
Cash From Financing Activities50,406,0001,326,0001,743,000
Change In Cash-45,521,000-38,644,00022,097,000
Cash At End Of Period60,181,000105,597,000145,647,000
Income Taxes Paid———
Interest Paid———
This is a preview of the latest data. Subscribe to access the full data.
Key Metrics
Fiscal Year202520242023
Earnings Per Share-16.06-1.31-0.93
Price To Earnings Ratio-1.9166-9.771-41.7204
Earnings Growth Rate1,125.954240.860225.6757
Price Earnings To Growth Ratio-0.0017-0.2391-1.6249
Book Value Per Share14.52071.46412.6095
Price To Book Ratio2.11978.742814.8685
Ebitda-262,909,000-323,363,000-214,382,000
Enterprise Value———
Dividend Yield———
Dividend Payout Ratio———
Debt To Equity Ratio———
Capital Expenditures-1,890,000-34,823,000-119,000
Free Cash Flow-148,134,000-127,571,000-163,575,000
Return On Equity-1.1057-0.896-0.3582
One Year Beta1.2492.17052.1384
Three Year Beta1.65421.82451.6051
Five Year Beta1.5671.68411.6051
This is a preview of the latest data. Subscribe to access the full data.
Insider Transactions
Insider NameRelationship To IssuerTransaction DateAmount Of SecuritiesAcquired Or DisposedSecurities Owned Following Transaction
Aguirre Jarrad MattieuChief Medical Officer2026-10-12422D19,857
Aguirre Jarrad MattieuChief Medical Officer2026-09-1047,500A47,500
Shook DavidChief Medical Officer2026-09-10500D20,423
Seely LynnDirector, President and CEO2026-08-219,589D63,899
Lee Gary K.Chief Scientific Officer2026-08-211,457D16,220
This is a preview of the latest data. Subscribe to access the full data.
Institutional Holdings
Investor NamePeriod Of ReportMarket ValueAmount Of SecuritiesPrice Per Security
Creative Planning2026-09-30241,53024,6719.79
Provenance Wealth Advisors, LLC2026-09-30421439.7907
Caitong International Asset Management Co., Ltd2026-09-30421439.7907
Mirae Asset Global Investments Co., Ltd.2026-09-3012,2571,2529.7899
China Universal Asset Management Co., Ltd.2026-09-3043,0564,4719.6301
This is a preview of the latest data. Subscribe to access the full data.
Mutual Fund Holdings
Registrant NamePeriod Of ReportFund NameFund SymbolAmount Of UnitsValue In UsdPercentage Value Compared To Assets
AMERICAN CENTURY ETF TRUST2026-08-31Avantis U.S. Small Cap Equity ETFAVSC24,100345,1120.0111
AMERICAN CENTURY ETF TRUST2026-08-31Avantis U.S. Equity ETFAVUS3464,954.720.0
Invesco Exchange-Traded Fund Trust II2026-08-31Invesco Nasdaq Biotechnology ETFIBBQ1,42820,448.960.0212
VANGUARD WORLD FUND2026-08-31ETF SharesVHT28,489407,962.480.0019
VANGUARD WORLD FUND2026-08-31Admiral SharesVHCIX28,489407,962.480.0019
This is a preview of the latest data. Subscribe to access the full data.